Abstract

PHARMACOLOGICAL MANAGEMENT OF NEURODEGENERATIVE DISEASE

Neha R. Jadhav*, Ashish N. Umale, Dr. Swati P. Deshmukh, Sharda K. Lokde, Prajwal P. Raghuwanshi and Arun V. Kamble

Abstract

The central nervous system (CNS), comprising the brain and spinal cord, serves as the body's essential control center. A key feature of this system is the blood-brain barrier, a semi-permeable membrane that shields the brain from harmful substances and toxins circulating in the blood. Neurological disorders, often marked by neuronal loss, include common neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Current treatments for Alzheimer’s disease involve drugs that exhibit anti-amyloid properties or mimic nerve growth factor activity. For Parkinson’s disease, dyskinesia is frequently linked to Ldopa therapy. Huntington’s disease treatments are exploring phase III drugs with anti-apoptotic effects, such as LAX 101. Therapies for rarer neurodegenerative disorders are being developed, often involving drugs with steroid-like activity.

Keywords: Alzheimer’s disease, Parkinson’s disease, Neurodegenerative disease.